AU2021266157A1 - Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa - Google Patents

Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa Download PDF

Info

Publication number
AU2021266157A1
AU2021266157A1 AU2021266157A AU2021266157A AU2021266157A1 AU 2021266157 A1 AU2021266157 A1 AU 2021266157A1 AU 2021266157 A AU2021266157 A AU 2021266157A AU 2021266157 A AU2021266157 A AU 2021266157A AU 2021266157 A1 AU2021266157 A1 AU 2021266157A1
Authority
AU
Australia
Prior art keywords
conjugate
dcn
tcrk
decorin
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021266157A
Other languages
English (en)
Inventor
Tero JÄRVINEN
Ulrike May
Toini PEMMARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tampere University Foundation SR
Original Assignee
Tampere University Foundation SR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tampere University Foundation SR filed Critical Tampere University Foundation SR
Publication of AU2021266157A1 publication Critical patent/AU2021266157A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2021266157A 2020-04-28 2021-04-28 Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa Pending AU2021266157A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063016359P 2020-04-28 2020-04-28
FI20205431 2020-04-28
US63/016,359 2020-04-28
FI20205431 2020-04-28
PCT/FI2021/050318 WO2021219940A1 (en) 2020-04-28 2021-04-28 Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa

Publications (1)

Publication Number Publication Date
AU2021266157A1 true AU2021266157A1 (en) 2022-12-08

Family

ID=75870661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021266157A Pending AU2021266157A1 (en) 2020-04-28 2021-04-28 Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa

Country Status (10)

Country Link
US (1) US20230167162A1 (https=)
EP (1) EP4142771A1 (https=)
JP (1) JP7824885B2 (https=)
KR (1) KR20230005314A (https=)
CN (1) CN115605218B (https=)
AU (1) AU2021266157A1 (https=)
BR (1) BR112022021879A2 (https=)
CA (1) CA3180694A1 (https=)
IL (1) IL297703A (https=)
WO (1) WO2021219940A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118001404B (zh) * 2024-02-06 2025-02-25 四川大学华西医院 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors

Also Published As

Publication number Publication date
CN115605218A (zh) 2023-01-13
CA3180694A1 (en) 2021-11-04
BR112022021879A2 (pt) 2022-12-20
JP2023523719A (ja) 2023-06-07
WO2021219940A1 (en) 2021-11-04
CN115605218B (zh) 2026-03-24
JP7824885B2 (ja) 2026-03-05
EP4142771A1 (en) 2023-03-08
IL297703A (en) 2022-12-01
US20230167162A1 (en) 2023-06-01
KR20230005314A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
US11224662B2 (en) Methods and therapeutics comprising ligand-targeted ELPs
US20160040142A1 (en) Csf1 therapeutics
JP6339231B2 (ja) 線維症性疾患の処置のためのＴｒａｉｌレセプターアゴニスト
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
US20190247317A1 (en) Icam-1 targeting elps
US9901620B2 (en) Trail receptor agonists for treatment of fibrotic disease
CN109789180A (zh) Kif13b衍生的肽和抑制血管生成的方法
JP7824885B2 (ja) 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体
CN109937045A (zh) 局部缺血/再灌注损伤
CN114409733A (zh) 靶向抑制mlkl乙酰化的多肽和/或其衍生物及其用途
Pemmari et al. Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa
JP2011529452A (ja) 抗血管新生薬としての可溶性ｉｇｆ受容体
HK1236396A1 (en) Trail receptor agonists for treatment of fibrotic diseases
HK1223556B (zh) Il-22二聚体在制备用於治疗胰腺炎的药物中的用途